Handicappers Debate Chances Of Genentech’s Avastin In Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
As clock ticks down to tomorrow’s user fee date for Avastin, “ambivalent and ambiguous” agency hard to outguess, analyst tells “The Pink Sheet” DAILY.